Introduction
Cardiovascular diseases are the major cause of death in the Western world, causing 17.9 million deaths per year (2015) . 1 The prevalence of cardiovascular diseases is influenced by many factors: age, nutritional habits, lifestyles or genetics. This complicates the co-development of treatments and the identification of universal biomarkers to stratify the population. To facilitate this segmentation, it is necessary to understand the molecular details of the treatment and the pathology.
Sacubitril/valsartan (marketed by Novartis as Entresto®) is a drug combination that improves the results of the conventional treatments by reducing cardiovascular deaths and heart failure (HF) readmissions. 2 In pharmacological terms, it is an angiotensin receptor-neprilysin inhibitor: it increases the natriuretic peptide system by inhibiting neprilysin (NEP) and inhibits reninangiotensin-aldosterone system by blocking the type-1 angiotensin II receptor (AT1R). 3 In a previous work, the Mechanism of Action (MoA) of sacubitril/valsartan synergy was unveiled: the synergistic effect of the drug combination was mainly reflected on left ventricular extracellular matrix remodelling, mediated by proteins like gap junction alpha-1 protein or matrix metalloproteinase-9, and also affects cardiomyocyte apoptosis through modulation of glycogen synthase kinase-3 beta. 4 However, several publications warned about the potential long-term negative implications of using a neprilysin inhibitor like sacubitril. 3, 5, 6 Neprilysin plays a critical role at maintaining the amyloid-homeostasis in the brain. The alteration of amyloid-levels could lead to the development of Alzheimer's disease or macular degeneration (MD). 7, 8 During the clinical trial PARADIGM-HF of sacubitril/valsartan, there were no serious effects detected. 2 However, the patient follow-up of PARADIGM-HF was relatively short and not specialised in finding neurodegenerative specific symptoms. For this reason, in the recent sacubitril/valsartan clinical trial PARAGON-HF, there will be a Mini Mental State exam, and in the forthcoming PERSPECTIVE trial there will be a battery of cognitive tests 6 ; however, any of the future studies will focus on potential MD consequences. A solution to explore the potential impact of sacubitril/valsartan on MD would be to apply computational methods that predict all the possible responses of the drug in the population. These computational simulations of real clinical trials are called In Silico Clinical Trials (ISCT), and they are based on systems biology principles.
Systems biology-based methods are increasingly becoming a reliable strategy to understand the molecular effects of a drug in complex clinical settings. However, current methodologies do not consider the inter-patient variability intrinsic to pharmacological treatments and thus miss relevant information that should be incorporated into the models. Indeed, there are many parameters influencing the MoA of such therapies, including demographic data of the patient, co-treatments or clinical history. The unexpected responses a patient might experience during a specific treatment could be explained by modeling the different mechanisms by which a drug exerts its effect on the patient. In this study, we will use the Therapeutic Performance Mapping System (TPMS) 9 to elucidate all the possible MoAs of a sacubitril/valsartan in MD. TPMS is a systems biology approach based on the simulation of patient-like characteristics. It has been broadly used in the last years in different clinical areas and with different objectives. 4, [10] [11] [12] [13] [14] The TPMS incorporates data from massive databases publicly available and experimental information obtained for the diseases and drugs under study to generate multiple models of potential MoAs.
Our hypothesis is that the set of MoAs could represent the different responses of the drug in cells and assume that a real population of patients is the result of a myriad of cell responses. Thus, a prototype-patient is defined as an abstract case with all cells responding with a single MoA. In this study, we analyse the population of MoAs associated with the response of HF and MD phenotypes to sacubitril/valsartan. We cluster the MoAs in groups by their response intensity. We analyse the MoAs with higher and lower susceptibility to treat HF and/or produce MD. We compare these MoAs and propose biomarkers to identify potential cases of MD when using sacubitril/valsartan. Finally, we use GUILDify v2.0 web server 15 to analyse the comorbidity of both phenotypes and analyse the relevance of the proposed biomarkers with a different approach.
Materials and Methods

Biological Effectors Database (BED) to molecularly describe specific clinical conditions
Biological Effectors Database (BED) describes more than 300 clinical phenotypes by means of gene and protein networks, which can be "active", "inactive" or "neutral". 10, 16 For example, in a metabolic network, proenzymes are "inactive" enzymes that become "active", or enzymes are inactivated when they interact with an inhibitor (see further details in supplementary material).
TPMS modelling of phenotypes.
The Therapeutic Performance Mapping System (TPMS) is a tool that creates mathematical models of a drug/pathology response to explain a clinical outcome or phenotype 4, [9] [10] [11] [12] [13] [14] . We applied TPMS to the drug-indication pair sacubitril/valsartan and HF: for the drug we retrieved and manually curated the sacubitril/valsartan targets from DrugBank 17 , PubChem 18 , STITCH 19 , SuperTarget 20 and hand curated literature revision, while for the indication we used the proteins associated with the phenotype from the BED. 10, 16 We defined the Human Protein Network (HPN) by integrating data on functions and interactions of proteins (see further details in supplementary material).
Defining restrictions from gene expression data
We define the state of human proteins as active or inactive for a particular phenotype, including its expression (as active) or repression (as inactive) extracted from the GSE57345 gene expression dataset 21 as in Iborra-Egea et al 4 (see further details in supplementary material).
Description of the mathematical models
The algorithm of TPMS uses as input signals the values of activation (+1) and inactivation (-1) of the drug protein targets. The outputs are then the values of activation and inactivation of the proteins defining the indication's phenotype (retrieved from the BED), named effectors. Each node of the protein network receives as input the output of the connected nodes and each link receives a weight ( # ). The sum of inputs is transformed by a hyperbolic tangent function to generate the score of the node, which becomes the "output signal" towards the connected nodes.
The # parameters are obtained by optimization, using a Stochastic Optimization Method based on Simulated Annealing. 22 The models are trained by using the restrictions defined by the BED and the specific conditions set by the user. We ranked all solutions by the number of restrictions satisfied and selected the top 200 solutions representing potential MoAs of the drug, which we assumed equally acceptable. Here, we hypothesized that these solutions can represent different cells, while combinations of them would correspond to different patients. Hence, 200 prototype or representative mathematical solutions can be considered for an individual and personalized approach. Details of the approach are shown in Figure 1 and supplementary material.
Measures to compare sets of MoAs
To understand the relationships between all potential mechanisms we defined measures of comparison between different sets of solutions. We expect that a drug will revert the conditions of a disease phenotype. Consequently, a drug should inactivate the active protein effectors of a pathology-phenotype and activate the inactive ones. Here, we defined several measures in order to study and compare sets of MoAs from different views (see further details in supplementary material).
TSignal
To quantify the intensity of the response of a MoA and compare it with others, we created a measure called TSignal. The TSignal is the average of the output signals of the protein effectors (equation in supplementary material).
Distance between two sets of MoAs
We calculated the distance between two or more sets of MoAs in order to determine their similarity. For that, we used a modified Hausdorff distance (MHD) introduced by Dubuisson and Jain. 23 Details of equations are in supplementary material. Each best-classifier protein has different output signals in the Low-and High-group MoAs and the distribution in both sets can be compared. We use a Mann-Whitney U test to compare the two distributions of output signals and select those proteins for which the difference is significant (p-value< 0.01), having an average output signal in Low-HF with opposite sign to the average output signal in High-HF (i.e. positive vs. negative or vice versa). We name these as differential bestclassifier proteins. By following this strategy, we can identify two groups of differential bestclassifier proteins: those active in Low-disease (positive output signal in average) and inactive in High-disease (negative output signal in average), and those active in High-disease and inactive in Low-disease.
Potential biomarkers extracted from MoAs
Results and discussion
We applied TPMS to the HPN using as input signals the drug targets of sacubitril/valsartan (NEP / AT1R) and as output signals the proteins associated with Heart Failure (HF) extracted from the BED. As described in the methodology, out of all MoAs found by TPMS, we selected 200 satisfying the largest number of restrictions (and at least 80% of them) to perform further analysis.
To rank the MoAs according to the intensity of the signal arriving from the drug, we calculated the TSignal of every MoA associated with HF and MD, i.e. the average output signal arriving to the protein effectors of both pathologies. According to the TSignal of HF and following the procedure described in Materials and Methods, we defined two groups of MoAs: Low-HF, containing the MoAs with a higher intensity of the response and therefore a healthier phenotype, and High-HF, with the MoAs of lower intensity of the response and therefore an increased HF disease phenotype. We also calculated the TSignal of MD and define two groups of MoAs: Low-MD, producing a reduced adverse effect, and High-MD, producing an increased adverse effect.
Note that TPMS was only executed once, optimising the results to satisfy the restrictions on HF data. The values of MD are obtained by measuring the signal arriving at the MD effectors, which are part of the HPN and also receive signal. This procedure was chosen because we treat HF as the indication of the drug (sacubitril/valsartan), while MD is a potential adverse effect.
In the following sections, we analysed and compared the four groups of MoAs and searched for biomarkers that can potentially identify MD as an adverse effect of the drug (and consequently classify patients). We used the web server GUILDify v2.0 15 to analyse the comorbidity of both phenotypes and analyse the relevance of the proposed biomarkers in a different context.
Limitations
Although TPMS returns the amount of signal from the drug arriving to the rest of the proteins in the HPN, this signal is only a qualitative measure. We are not using data about the dosage of the drug or the quantity of expression of the proteins. However, we are already working to make TPMS move towards the growing tendency of Quantitative Systems Pharmacology. The quantification of the availability of drugs in the target tissue for each patient opens the opportunity to have an accurate patient simulation to do in silico clinical trials.
Conclusions
There is a need of systems biology-based methods to simulate the different responses of a drug in patients. The specific case of sacubitril/valsartan stands out because of the amount of resources invested in the safety of the drug and the concern on the risk of MD. In this study, we apply TPMS to uncover the different MoAs of sacubitril/valsartan over HF and reveal its relationship with MD. We hypothesize that all MoAs coexist in cells, but in a population of patients some cells may have more proclivity to certain MoAs than others. We define a prototype-patient as one with a single MoA for a drug and study the in silico trial of HF treatment with sacubitril/valsartan and its potential adverse effect MD. TPMS achieves this by modelling an accurate representation of the HPN and applying a Multilayer Perceptron-like and sampling method strategy to find all plausible solutions. We found that HF low responder MoAs are more associated to MD development at the same time, although good responders are also associated to MD. Different sets of proteins have been found to classify the mechanisms according to HF and MD response, which include functions such as PI3K and MAPK kinase signalling pathways, involved in HF-related cardiac hypertrophy, or fibrinolysis and coagulation processes (e.g. FGB, SERPINE1 or SERPING1) and growth factors (e.g. FGF1 or PDGF) related to MD induction. We propose 30 biomarkers to identify patients potentially developing MD under the successful treatment with sacubitril/valsartan. Out of this 30, we propose 10 biomarkers that have been found to be involved in the comorbidity between HF and MD predicted by a different approach (GUILDify), including well-known HF and MD effectors also related to the mechanisms of sacubitril/valsartan and/or HF, such as AGER, NRG1, ITGB5 or IL1A. 
